Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference
Cytokinetics (CYTK) has announced its participation in the 2024 Jefferies London Healthcare Conference. The company will engage in a fireside chat scheduled for Tuesday, November 19, 2024, at 4:00 PM GMT at The Waldorf Hilton Hotel in London.
A live webcast of the discussion will be accessible through the Investors & Media section of Cytokinetics' website. The replay will remain available on the company's website for 90 days after the event concludes.
Cytokinetics (CYTK) ha annunciato la sua partecipazione alla Jefferies London Healthcare Conference 2024. L'azienda prenderà parte a una chiacchierata in focolare in programma per martedì 19 novembre 2024, alle 16:00 GMT presso il Waldorf Hilton Hotel di Londra.
Un webcast dal vivo della discussione sarà accessibile attraverso la sezione Investitori e Media del sito web di Cytokinetics. La registrazione rimarrà disponibile sul sito dell'azienda per 90 giorni dopo la conclusione dell'evento.
Cytokinetics (CYTK) ha anunciado su participación en la Conferencia de Salud Jefferies de Londres 2024. La compañía participará en una conversación programada para el martes 19 de noviembre de 2024, a las 4:00 PM GMT en el Hotel Waldorf Hilton de Londres.
Una transmisión en vivo de la discusión estará disponible a través de la sección de Inversores y Medios en el sitio web de Cytokinetics. La grabación estará disponible en el sitio web de la empresa durante 90 días después de que finalice el evento.
Cytokinetics (CYTK)는 2024 제프리스 런던 헬스케어 회의에 참가한다고 발표했습니다. 이 회사는 2024년 11월 19일 화요일, GMT 기준 오후 4시에 런던의 월도프 힐튼 호텔에서 예정된 대화에 참여할 것입니다.
토론의 생중계는 Cytokinetics의 웹사이트의 투자자 및 미디어 섹션을 통해 접근할 수 있습니다. 이벤트가 종료된 후 90일 동안 회사 웹사이트에서 다시 재생할 수 있습니다.
Cytokinetics (CYTK) a annoncé sa participation à la Conférence de Santé Jefferies de Londres 2024. La société prendra part à une discussion prévue pour le mardi 19 novembre 2024, à 16h00 GMT à l'Hôtel Waldorf Hilton à Londres.
Une retransmission en direct de la discussion sera accessible via la section Investisseurs et Médias du site web de Cytokinetics. La rediffusion restera disponible sur le site de l'entreprise pendant 90 jours après la fin de l'événement.
Cytokinetics (CYTK) hat seine Teilnahme an der 2024 Jefferies London Healthcare Conference bekannt gegeben. Das Unternehmen wird an einem geplanten Fireside-Chat am Dienstag, den 19. November 2024, um 16:00 Uhr GMT im Waldorf Hilton Hotel in London teilnehmen.
Ein Live-Stream der Diskussion wird über den Bereich Investoren und Medien auf der Website von Cytokinetics zugänglich sein. Die Aufzeichnung wird für 90 Tage nach Abschluss der Veranstaltung auf der Unternehmenswebsite verfügbar bleiben.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 4:00 PM Greenwich Mean Time at The Waldorf Hilton Hotel in London, England.
Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial evaluating aficamten, a next-in-class cardiac myosin inhibitor, in obstructive hypertrophic cardiomyopathy (HCM), Cytokinetics submitted an NDA for aficamten to the U.S. Food & Drug Administration and is progressing regulatory submissions for aficamten for the treatment of obstructive HCM in Europe. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of heart failure with preserved ejection fraction (HFpEF), and CK-089, a fast skeletal muscle troponin activator (FSTA) with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired muscle function.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
When is Cytokinetics (CYTK) presenting at the 2024 Jefferies London Healthcare Conference?
Where can I watch Cytokinetics' (CYTK) fireside chat from the 2024 Jefferies Conference?
How long will the replay of Cytokinetics' (CYTK) 2024 Jefferies Conference presentation be available?